Transcriptomic signature predicts the distant relapse in patients with ER+ breast cancer treated with tamoxifen for five years
Excerpt:
...a multi‑gene expression based risk score was developed and was revealed as being able to successfully predict the outcome of patients with ER+ breast cancer treated with tamoxifen for 5 years.